Analysis Of The Weekly Performance Of Eli Lilly and Company (LLY)


Eli Lilly and Company (NYSE:LLY) finished Wednesday with a subtraction of -$5.25 to close at $296.48, a downside of -1.74 percent. An average of 2,660,320 shares of common stock have been traded in the last five days. There was a fall of -$13.13 in the past week, and it reached a new high 30 times over the past 12 months. The last 20 days have seen an average of 2,329,115 shares traded, while the 50-day average volume stands at 2,500,288.

LLY stock has decreased by -8.24% in the last month. The company shares reached their 1-month lowest point of $296.32 on 09/21/22. With the stock rallying to its 52-week high on 07/15/22, shares of the company touched a low of $220.20 and a high of $335.33 in 52 weeks. It has reached a new high 15 times so far this year and achieved 7.33% or $20.26 in price. In spite of this, the price is down -11.59% from the 52-week high.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Insider Transactions

21 days have passed since Eli Lilly and Company (LLY) last reported insider trading activity. Zakrowski Donald A, who is Chief Accounting Officer, most recently acquired $1,000 shares at $301.00 per share on Sep 01. In this transaction, the insider spent $301,000. SVP, ERM & CECO, Weems Alonzo, disposed of 656 shares at a price of $304.50 on Aug 10. The insider now owns more than $199,752 worth of shares. Prior to that, 10% Owner LILLY ENDOWMENT INC went on to Sale 89,458 shares at $332.85 each on Jul 28. An amount of $29,776,514 was transacted.

Valuation Metrics

Eli Lilly and Company (LLY) has a trailing price-to-earnings (P/E) ratio of 47.31. The stock’s beta is 0.37. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 9.71, the price-to-book (PB) ratio at 31.24, and the price-to-cash flow ratio at 116.14.

The company has a payout ratio of 58.10%. The company’s most recent quarterly dividend payment was $0.98 a share, without any change from last year. Its latest increase dividend $0.13 reported on Monday December 13 2021.

Financial Health

The quick ratio of Eli Lilly and Company for the three months ended June 29 was 0.80, and the current ratio was 1.10, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.72 and a total debt to equity ratio of 1.97 for the quarter ending June 29. Its gross profit as reported stood at $21.01 billion compared to revenue of $28.32 billion.

Earnings Surprise

For the three-month period that ended June 29, Eli Lilly and Company had $113.8 million in cash and short-term investments compared to $14.69 billion in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $952.5 million in the quarter, while revenues of $1.9 billion were shrunk -45.95%. The analyst consensus anticipated Eli Lilly and Company’s latest quarter earnings to come in at $1.72 per share, but it turned out to be $1.25, a -27.30% surprise. For the quarter, EBITDA amounted to $1.56 billion. Shareholders own equity worth $950.17 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Eli Lilly and Company (LLY) price momentum. RSI 9-day as of the close on 21 September was 31.69%, suggesting the stock is Neutral, with historical volatility in this time frame at 17.13%.

As of today, LLY’s price is $304.33 -4.24% or -$13.13 from its 5-day moving average. LLY is currently trading -5.91% lower than its 20-day SMA and -0.27% lower than its 100-day SMA. However, the stock’s current price level is -8.38% below the SMA50 and +20.73% above the SMA200.

The stochastic %K and %D were 17.06% and 29.08%, respectively, and the average true range (ATR) was 7.57. With the 14-day stochastic at 0.66% and the average true range at 7.57, the RSI (14) stands at 37.42%. The stock has reached -6.75 on the 9-day MACD Oscillator while the 14-day reading was at -7.12.

Analyst Ratings

SVB Leerink launched coverage on Eli Lilly and Company (NYSE: LLY) in its analyst report released on May 23, 2022. The firm assigned the stock an Outperform rating. The consensus rating for Eli Lilly and Company (LLY) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell LLY, while 7 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 2 analysts, while 12 others rate it as a “buy”.

What is LLY’s price target for the next 12 months?

Analysts predict a range of price targets between $202.00 and $412.00, with a median target of $349.00. Taking a look at these predictions, the average price target given by analysts for Eli Lilly and Company (LLY) stock is $339.70.


Please enter your comment!
Please enter your name here